Z
Zentalis Pharmaceuticals, Inc. (ZNTL)
NGM – Real Time Price. Currency in USD
2.10
-0.57 (-21.35%)
At close: Mar 27, 2026, 4:00 PM EDT
2.17
+0.07 (3.33%)
After-hours: Mar 27, 2026, 7:11 PM EDT

NGM – Real Time Price. Currency in USD
2.10
-0.57 (-21.35%)
At close: Mar 27, 2026, 4:00 PM EDT
2.17
+0.07 (3.33%)
After-hours: Mar 27, 2026, 7:11 PM EDT
No Data
There are no news for this stock.
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 7.76 | 6.05 | 10 | |
| Quick ratio | 7.76 | 5.63 | 10 | |
| Debt to Equity | 0.16 | 0.30 | 9.0 | |
| Debt to Assets | 0.12 | 1.04 | 8.0 | |
| Interest coverage | N/A | -16.91 | 1.0 | |
| Weighted average score | 7.6 | |||
| METRIC | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|
| Total Revenue | N/A | N/A | N/A | 67M | 27M |
| Gross Profit | -544K | -1M | -1M | 66M | 26M |
| Operating Income | -208M | -227M | -254M | -187M | -153M |
| Net Income | -159M | -237M | -292M | -166M | -149M |
| EBITDA | -207M | -226M | -253M | -186M | -152M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | -100 | 36.32 | 5.5 |
| Next quarter | N/A | 30.28 | 5.5 |
| Current year | -100 | 21.73 | 5.5 |
| Next year | N/A | -2.09 | 1.0 |
| Weighted average score | 4.4 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 999 | 0.68 | 0 | 22.31 | 5.8 |
| Y/Y | 999 | 33.54 | 33.93 | 38.78 | 10 |
| 3y average | 999 | -9.76 | 9.22 | -3.72 | 4.5 |
| 5y average | 999 | -44.4 | 17.55 | -43.16 | 5.3 |
| Weighted average score | 6.4 | ||||
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |
Cash reserves $39.1M barely cover the upcoming debt maturities $40.5M
Total current assets $288.3M exceed Total current liabilities $37.2M, highlighting excellent liquidity
Debt-to-equity ratio (0.2) is well below the industry average (0.3), showcasing prudent financial management
Interest expense exists but EBIT data is unavailable, indicating potential profitability concerns
Negative free cash flow -$27.0M limits the company's ability to reinvest or pay down debt